Drug Approval | February 23, 2023
Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
In a bid to better leverage its clinical expertise and drive quality reporting across its centres, Thyrocare has added SigTuple’s AI100 to automate the microscopic review in its laboratories
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated
